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Cystic Fibrosis Mutations in Heterozygous Newborns
with Hypertrypsinemia and Low Sweat Chloride
To the Editor:
Measurement of immunoreactive trypsinogen concen-
tration (IRT) in dried blood spots is the most common
technique for cystic fibrosis (CF) neonatal screening.
Since a considerable number of newborns show raised
IRT levels, the screening specificity is often improved by
determining whether infants with hypertrypsinemiahave
the most common CF mutations: diagnosis is established
in neonates carrying two mutations, but a sweat test is
required if only one mutation is found, to distinguish
between affected individuals—who would have a sec-
ond, unrecognized mutation—and heterozygotes. In-
fants with raised IRT, one CF mutation, and normal
sweat electrolyte concentrations are usually considered
to be carriers only. However, the carrier frequency
among nonaffected IRT-positive babies is almost three
times higher than that in the general population (Laroche
et al. 1991; Castellani et al. 1997); this could be partially
explained if some of these babies carry on the other
chromosome a mild mutation, associated with scarce
symptoms and normal sweat chloride values. A DNA
polymorphic sequence of five thymines (TTTTT) in in-
tron 8 of the CF transmembrane conductance regulator
(CFTR) gene, which is very common in men with a pri-
marily genital CF form called “congenital bilateral
absence of the vas deferens” (CBAVD) (Chillon et al.
1995), has been found to occur more frequently in new-
borns with raised IRT values than in controls (Castellani
et al. 1997; Chin et al. 1997). To look further into the
hypothesis that, in at least some babies, raised trypsin
levels at birth could be a phenotypic expression of a
compound heterozygosity, we investigated a subset of
18 newborns, using the following selection criteria: IRT
199.5 percentile; one identified CFTR mutation among
a panel of 15 mutations that are present in 85% of the
CF chromosomes in our area; normal sweat chloride, as
determined by pilocarpine iontophoresis (mean 16.9
mEq/liter; maximum 32 mEq/liter; minimum 6 mEq/li-
ter). In these neonates and in a control group of 15
healthy subjects (Pignatti et al. 1995), novel and rare
mutations of the CFTR gene were sought by use of a
complete gene search, with denaturing gradient-gel–
electrophoresis analysis of all 27 exons and intronic
flanking regions. PCR products that displayed an altered
behavior in the gel were sequenced after cloning. Seven
CFTR gene mutations were found in eight IRT-positive
newborns, compared with one mutation (L997F) in the
control group ( by Fisher’s exact test; see tableP  .02
1). Three of these mutations (R117H, Y301C, and
E527G) are thought to be disease causing in CF or in
CBAVD, since they determine the substitution of an
amino acid in evolutionarily conserved residues and
therefore are tentatively classified, on the basis of the
Cystic Fibrosis Genetic Analysis Consortium (CFGAC)
database, as “mutations”; the other four mutations
(1716 G/A, 262214 G/A, 3041-71 G/C, and 4002 A/
G) are not believed to be disease causing in CF and
CBAVD, either because they do not determine any amino
acid substitutions (in the case of 1716 G/A and 4002 A/
G) or because they occur in noncoding regions that, as
determined by sequence-analysis software, produce no
apparent alteration (in the case of 262214 G/A and
3041-71 G/C) and therefore are tentatively classified, on
the basis of the CFGAC database, as CF “polymor-
phisms.” Mutations E527G and 262214G/A are de-
scribed here for the first time. It is problematic to
understand the clinical significance of the detected
“mutations not supposed to cause CF,” but, as far as
“mutations supposed to cause CF” are concerned, in the
3 (16.6%) of 18 newborns who were compound het-
erozygous, the raised IRT probably was not a casual
finding but was a biochemical sign of an only partially
functioning CFTR protein. Whether these neonates
ought to be diagnosed as affected with CF is a moot
point. In ∼2% of patients with CF, there is an “atypical”
phenotype, which consists of chronic sinopulmonary dis-
ease, pancreatic sufficiency, and either borderline or nor-
mal sweat chloride concentrations (Rosenstein et al.
1998). Unfortunately, it is not possible at present to pre-
dict the clinical outcome of our newborns, nor is it pos-
sible to provide satisfactory genetic counseling for the
family. A close clinical follow-up should help in clari-
fying the extent of the disease in these subjects.
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Table 1
Sweat Chloride Concentration and CFTR Genotypes
CASE
SWEAT
CHLORIDE
(mEq/liter)
MUTATION
Allele 1a Allele 2b
1 10 R1162X 3041-71G/C,c
4002A/Gc
2 14 DF508
3 30 R1162X R117H
4 21 DF508 E527G
5 8 DF508
6 12 N1303K,
262214G/Ad
7 6 DF508
8 20 DF508 1716G/Ac
9 16 DF508
10 10 DF508
11 19 R1162X
12 19 N1303K
13 12 G542X 1716G/Ac
14 32 DF508
15 14 DF508
16 26 N1303K 262214G/Ac
17 18 DF508 Y301C
18 18 2183AArG
a First mutation found, assigned to one gene.
b Second mutation found, assigned to the gene other
than that to which the first mutation found was assigned.
c Mutation located in allele 1 or allele 2 (no segre-
gation analysis was possible, since the parents were not
available for testing).
d Mutation located in the same gene.
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